Pediatric RSV Vaccine
Imaginations Should Run Wild. Not RSV.
Clinical Trial for Children and Teens 2 to 17 Years of Age
We are looking for children and teens 2 to 17 years of age to participate in the Imagine Trial. This clinical trial is for an investigational vaccine aimed at preventing respiratory syncytial virus (RSV).
About the Imagine Trial
Young children are one of the vulnerable groups at risk for RSV infection. RSV is a common respiratory virus that targets the lungs and breathing passages and is easily spread from child to child. Globally in 2019, RSV caused 33 million respiratory infections in children 5 years of age and younger.¹
RSV infection may also be severe in children with a variety of medical or chronic conditions.² Children living with a chronic condition who get RSV may have a higher likelihood for hospitalization, a longer hospital stay, or a need for oxygen therapy.²
The Imagine Trial is evaluating the safety and immune response of an investigational vaccine aimed at preventing RSV disease in children and teens 2 to 17 years of age. Participants 2 to 4 years of age will receive either the investigational vaccine, mRNA-1345, or a placebo, which contains no active ingredients. Participants 5 years of age or older will receive the investigational vaccine, mRNA-1345. Participating in this trial will help advance research that may potentially change how we protect children and teens from RSV disease.
Who Can Join?
The Imagine Trial is looking for children and teens who are:
- 2 to 4 years of age and in good health
- 2 to 17 years of age and have a condition that increases the risk of RSV, including
asthma, congenital heart disease, cystic fibrosis, Down syndrome, lung disease (and malformations of the lung), neuromuscular disease (such as cerebral palsy), and sickle cell disease
The total length of participation in this clinical trial is approximately 7 months. It includes at least 2 in-person visits and 2 phone calls with the clinical trial team. Clinical trial participants will be given 1 injection in the arm.
Diseases do not discriminate — and neither should clinical trials.
Moderna is committed to researching safe and effective mRNA-based vaccines and therapies to bring better health and living to people of all ages, sexes, and backgrounds.
Contact the Clinical Trial Team Today
- Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-2064. doi:10.1016/S0140-6736(22)00478-0
- Manzoni P, Figueras-Aloy J, Simões EAF, et al. Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases. Infect Dis Ther. 2017;6(3):383-411. doi:10.1007/s40121-017- 0160-3